These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24034450)

  • 1. Evaluation of the profibrinolytic properties of a bispecific antibody-based inhibitor against human and mouse thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1.
    Wyseure T; Gils A; Declerck PJ
    J Thromb Haemost; 2013 Nov; 11(11):2069-71. PubMed ID: 24034450
    [No Abstract]   [Full Text] [Related]  

  • 2. No increased systemic fibrinolysis in women with heavy menstrual bleeding.
    Wiewel-Verschueren S; Knol HM; Lisman T; Bogchelman DH; Kluin-Nelemans JC; van der Zee AG; Mulder AB; Meijer K
    J Thromb Haemost; 2014 Sep; 12(9):1488-93. PubMed ID: 24954113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.
    Semeraro F; Ammollo CT; Semeraro N; Colucci M
    Haematologica; 2009 Jun; 94(6):819-26. PubMed ID: 19377079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel or expanding current targets in fibrinolysis.
    Wyseure T; Declerck PJ
    Drug Discov Today; 2014 Sep; 19(9):1476-82. PubMed ID: 24886765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
    J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
    J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bidirectional functions of thrombin on fibrinolysis: Evidence of thrombin-dependent enhancement of fibrinolysis provided by spontaneous plasma clot lysis.
    Tomczyk M; Suzuki Y; Sano H; Brzoska T; Tanaka H; Urano T
    Thromb Res; 2016 Jul; 143():28-33. PubMed ID: 27179129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secreted Bacillus anthracis proteases target the host fibrinolytic system.
    Chung MC; Jorgensen SC; Tonry JH; Kashanchi F; Bailey C; Popov S
    FEMS Immunol Med Microbiol; 2011 Jul; 62(2):173-81. PubMed ID: 21395696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basic principles in thrombolysis: regulatory role of plasminogen.
    Rijken DC; Sakharov DV
    Thromb Res; 2001 Sep; 103 Suppl 1():S41-9. PubMed ID: 11567668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody.
    Hendrickx ML; Zatloukalova M; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
    Thromb Haemost; 2014 May; 111(5):824-32. PubMed ID: 24402608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifibrinolytic mechanisms in acute airway injury after sulfur mustard analog inhalation.
    Rancourt RC; Ahmad A; Veress LA; Rioux JS; Garlick RB; White CW
    Am J Respir Cell Mol Biol; 2014 Oct; 51(4):559-67. PubMed ID: 24796565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
    Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
    J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism.
    Orbe J; Barrenetxe J; Rodriguez JA; Vivien D; Orset C; Parks WC; Birkland TP; Serrano R; Purroy A; Martinez de Lizarrondo S; Angles-Cano E; Páramo JA
    Circulation; 2011 Dec; 124(25):2909-19. PubMed ID: 22104553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models.
    Leenaerts D; Loyau S; Mertens JC; Boisseau W; Michel JB; Lambeir AM; Jandrot-Perrus M; Hendriks D
    J Thromb Haemost; 2018 Oct; 16(10):2057-2069. PubMed ID: 30053349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model.
    Vercauteren E; Emmerechts J; Peeters M; Hoylaerts MF; Declerck PJ; Gils A
    Blood; 2011 Apr; 117(17):4615-22. PubMed ID: 21343611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody.
    Develter J; Booth NA; Declerck PJ; Gils A
    J Thromb Haemost; 2008 Nov; 6(11):1884-91. PubMed ID: 18752580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.
    Zhou J; Kochan J; Yin O; Warren V; Zamora C; Atiee G; Pav J; Orihashi Y; Vashi V; Dishy V
    J Thromb Haemost; 2017 May; 15(5):961-971. PubMed ID: 28211169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
    Schaffner AP; Sansilvestri-Morel P; Despaux N; Ruano E; Persigand T; Rupin A; Mennecier P; Vallez MO; Raimbaud E; Desos P; Gloanec P
    J Med Chem; 2021 Apr; 64(7):3897-3910. PubMed ID: 33764059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood.
    Carrieri C; Galasso R; Semeraro F; Ammollo CT; Semeraro N; Colucci M
    J Thromb Haemost; 2011 Jan; 9(1):154-62. PubMed ID: 20961395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor XII-dependent increases in thrombin activity induce carboxypeptidase-mediated attenuation of pharmacological fibrinolysis.
    Latacha MP; Schaiff WT; Eisenberg PR; Abendschein DR
    J Thromb Haemost; 2004 Jan; 2(1):128-34. PubMed ID: 14717976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.